Corvus Pharmaceuticals, Inc. (CRVS) stock
CRVSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.64+0.02 (+0.19%)
Close on Nov 13, 2026Market cap $895.05MP/E –Yield –
Corvus Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Corvus Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $54.86M, up 84.4% year over year. For fiscal 2025 it was $33.72M, up 73.9% from the year before. Over ten years it grew 11.5% a year on average. The highest annual figure on record is $46.31M in fiscal 2017.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $33.72M | +73.9% |
| FY2024 | Dec 31, 2024 | $19.39M | +17.3% |
| FY2023 | Dec 31, 2023 | $16.53M | -32.5% |
| FY2022 | Dec 31, 2022 | $24.47M | -16.0% |
| FY2021 | Dec 31, 2021 | $29.12M | -8.5% |
| FY2020 | Dec 31, 2020 | $31.83M | -16.2% |
| FY2019 | Dec 31, 2019 | $37.98M | -1.6% |
| FY2018 | Dec 31, 2018 | $38.59M | -16.7% |
| FY2017 | Dec 31, 2017 | $46.31M | +57.7% |
| FY2016 | Dec 31, 2016 | $29.36M | +158.6% |
| FY2015 | Dec 31, 2015 | $11.35M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $17.78M | +110.3% |
| Q2 FY2026 | Jun 30, 2026 | $15.96M | +102.8% |
| Q1 FY2026 | Mar 31, 2026 | $11.18M | +49.9% |
| Q4 FY2025 | Dec 31, 2025 | $9.94M | +66.4% |
| Q3 FY2025 | Sep 30, 2025 | $8.45M | +61.9% |
| Q2 FY2025 | Jun 30, 2025 | $7.87M | +91.4% |
| Q1 FY2025 | Mar 31, 2025 | $7.45M | +82.9% |
| Q4 FY2024 | Dec 31, 2024 | $5.97M | +49.4% |
| Q3 FY2024 | Sep 30, 2024 | $5.22M | +31.7% |
| Q2 FY2024 | Jun 30, 2024 | $4.11M | +3.7% |
| Q1 FY2024 | Mar 31, 2024 | $4.08M | -11.3% |
| Q4 FY2023 | Dec 31, 2023 | $4.00M | -2.0% |
| Q3 FY2023 | Sep 30, 2023 | $3.97M | -61.7% |
| Q2 FY2023 | Jun 30, 2023 | $3.97M | -19.4% |
| Q1 FY2023 | Mar 31, 2023 | $4.59M | -9.9% |
| Q4 FY2022 | Dec 31, 2022 | $4.08M | -14.8% |
| Q3 FY2022 | Sep 30, 2022 | $10.37M | +48.3% |
| Q2 FY2022 | Jun 30, 2022 | $4.92M | -45.9% |
| Q1 FY2022 | Mar 31, 2022 | $5.10M | -38.0% |
| Q4 FY2021 | Dec 31, 2021 | $4.79M | -33.4% |
| Q3 FY2021 | Sep 30, 2021 | $6.99M | +5.6% |
| Q2 FY2021 | Jun 30, 2021 | $9.11M | +15.9% |
| Q1 FY2021 | Mar 31, 2021 | $8.23M | -19.0% |
| Q4 FY2020 | Dec 31, 2020 | $7.19M | -19.4% |
| Q3 FY2020 | Sep 30, 2020 | $6.62M | -26.4% |
| Q2 FY2020 | Jun 30, 2020 | $7.86M | -26.2% |
| Q1 FY2020 | Mar 31, 2020 | $10.16M | +7.9% |
| Q4 FY2019 | Dec 31, 2019 | $8.92M | +6.3% |
| Q3 FY2019 | Sep 30, 2019 | $9.00M | +7.4% |
| Q2 FY2019 | Jun 30, 2019 | $10.64M | +9.5% |
| Q1 FY2019 | Mar 31, 2019 | $9.42M | -22.2% |
| Q4 FY2018 | Dec 31, 2018 | $8.39M | -13.4% |
| Q3 FY2018 | Sep 30, 2018 | $8.37M | -22.0% |
| Q2 FY2018 | Jun 30, 2018 | $9.72M | -21.6% |
| Q1 FY2018 | Mar 31, 2018 | $12.10M | -10.3% |
| Q4 FY2017 | Dec 31, 2017 | $9.69M | +6.1% |
| Q3 FY2017 | Sep 30, 2017 | $10.73M | – |
| Q2 FY2017 | Jun 30, 2017 | $12.39M | – |
| Q1 FY2017 | Mar 31, 2017 | $13.50M | – |
| Q4 FY2016 | Dec 31, 2016 | $9.13M | – |
See a number that looks wrong?